Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys

被引:44
|
作者
Shemesh, Colby S. [1 ]
Yu, Rosie Z. [1 ]
Gaus, Hans J. [2 ]
Greenlee, Sarah [1 ]
Post, Noah [1 ]
Schmidt, Karsten [2 ]
Migawa, Michael T. [3 ]
Seth, Punit P. [3 ]
Zanardi, Thomas A. [4 ]
Prakash, Thazha P. [3 ]
Swayze, Eric E. [3 ]
Henry, Scott P. [4 ]
Wang, Yanfeng [1 ]
机构
[1] IONIS Pharmaceut, Dept Pharmacokinet & Clin Pharmacol, 2855 Gazelle Ct, Carlsbad, CA 92010 USA
[2] IONIS Pharmaceut, Struct Biol, Carlsbad, CA 92010 USA
[3] IONIS Pharmaceut, Med Chem, Carlsbad, CA 92010 USA
[4] IONIS Pharmaceut, Toxicol, Carlsbad, CA 92010 USA
来源
关键词
antisense oligonucleotide; biotransformation; metabolism; N-acetyl galactosamine; targeted drug delivery; TARGETED DELIVERY; MASS-SPECTROMETRY; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; ASIALOGLYCOPROTEIN RECEPTOR; MOLECULAR-MECHANISMS; APOLIPOPROTEIN B-100; DRUG DEVELOPMENT; METABOLISM; THERAPEUTICS; LIVER;
D O I
10.1038/mtna.2016.31
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Triantennary N-acetyl galactosamine (GalNAc(3)) is a high-affinity ligand for hepatocyte-specific asialoglycoprotein receptors. Conjugation with GalNAc(3) via a trishexylamino (THA)-C6 cluster significantly enhances antisense oligonucleotide (ASO) potency. Herein, the biotransformation, disposition, and elimination of the THA cluster of ION-681257, a GalNAc(3)-conjugated ASO currently in clinical development, are investigated in rats and monkey. Rats were administered a single subcutaneous dose of H-3-radiolabeled (H-3 placed in THA) or nonradiolabeled ION-681257. Mass balance included radiometric profiling and metabolite fractionation with characterization by mass spectrometry. GalNAc(3)-conjugated ASOs were extensively distributed into liver. The THA-C6 triantenerrary GalNAc(3) conjugate at the 5'-end of the ASO was rapidly metabolized and excreted with 25.67 +/- 1.635% and 71.66 +/- 4.17% of radioactivity recovered in urine and feces within 48 hours postdose. Unchanged drug, short-mer ASOs, and linker metabolites were detected in urine. Collectively, 14 novel linker associated metabolites were discovered including oxidation at each branching arm, initially by monooxidation at the beta-position followed by dioxidation at the alpha-arm, and lastly, tri and tetra oxidations on the two remaining beta-arms. Metabolites in bile and feces were identical to urine except for oxidized linear and cyclic linker metabolites. Enzymatic reaction phenotyping confirmed involvement of N-acetyl-beta-glucosaminidase, deoxyribonuclease II, alkaline phosphatase, and alcohol + aldehyde dehydrogenases on the complex metabolism pathway for THA supplementing in vivo findings. Lastly, excreta from monkeys treated with ION-681257 revealed the identical series as observed in rat. In summary, our findings provide an improved understanding of GalNAc(3)-conjugated-ASO metabolism pathways which facilitate similar development programs.
引用
收藏
页数:16
相关论文
共 22 条
  • [1] Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys
    Yu, Rosie Z.
    Gunawan, Rudy
    Post, Noah
    Zanardi, Thomas
    Hall, Shannon
    Burkey, Jennifer
    Kim, Tae-Won
    Graham, Mark J.
    Prakash, Thazha P.
    Seth, Punit P.
    Swayze, Eric E.
    Geary, Richard S.
    Henry, Scott P.
    Wang, Yanfeng
    NUCLEIC ACID THERAPEUTICS, 2016, 26 (06) : 372 - 380
  • [3] Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
    Wang, Yanfeng
    Yu, Rosie Z.
    Henry, Scott
    Geary, Richard S.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (06) : 475 - 485
  • [4] Integrated Assessment of Phase 2 Data on GalNAc3-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
    Baker, Brenda F. F.
    Xia, Shuting
    Partridge, Wesley
    Kwoh, T. Jesse
    Tsimikas, Sotirios
    Bhanot, Sanjay
    Geary, Richard S. S.
    NUCLEIC ACID THERAPEUTICS, 2023, 33 (01) : 72 - 80
  • [5] Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
    Yu, Rosie Z.
    Graham, Mark J.
    Post, Noah
    Riney, Stan
    Zanardi, Thomas
    Hall, Shannon
    Burkey, Jennifer
    Shemesh, Colby S.
    Prakash, Thazha P.
    Seth, Punit P.
    Swayze, Eric E.
    Geary, Richard S.
    Wang, Yanfeng
    Henry, Scott
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2016, 5 : e317
  • [6] Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs
    Shemesh, Colby S.
    Yu, Rosie Z.
    Warren, Mark S.
    Liu, Michael
    Jahic, Mirza
    Nichols, Brandon
    Post, Noah
    Lin, Song
    Norris, Daniel A.
    Hurh, Eunju
    Huang, Jane
    Watanabe, Tanya
    Henry, Scott P.
    Wang, Yanfeng
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 9 : 34 - 47
  • [7] Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
    Crooke, Stanley T.
    Baker, Brenda F.
    Xia, Shuting
    Yu, Rosie Z.
    Viney, Nicholas J.
    Wang, Yanfeng
    Tsimikas, Sotirios
    Geary, Richard S.
    NUCLEIC ACID THERAPEUTICS, 2019, 29 (01) : 16 - 32
  • [8] Safety and Tolerability of GalNAc3-Conjugated Antisense Drugs Compared to the Same-Sequence 2′-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data
    Baker, Brenda F.
    Xia, Shuting
    Partridge, Wesley
    Engelhardt, Jeffery A.
    Tsimikas, Sotirios
    Crooke, Stanley T.
    Bhanot, Sanjay
    Geary, Richard S.
    NUCLEIC ACID THERAPEUTICS, 2024, 34 (01) : 18 - 25
  • [9] Identification of GalNAc-Conjugated Antisense Oligonucleotide Metabolites Using an Untargeted and Generic Approach Based on High Resolution Mass Spectrometry
    Husser, Christophe
    Brink, Andreas
    Zell, Manfred
    Mueller, Martina B.
    Koller, Erich
    Schadt, Simone
    ANALYTICAL CHEMISTRY, 2017, 89 (12) : 6821 - 6826
  • [10] Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects
    Gane, Edward J.
    Yuen, Man-Fung
    Schwabe, Christian
    Wu, Min
    Le, Kha
    Rito, Jen
    Gupta, Kusum
    Westland, Christopher
    Lai, Felix
    Venkatraman, Meenakshi
    Fitzgerald, Megan
    Lin, Tse-I
    Blatt, Lawrence
    Chanda, Sushmita
    McClure, Matt
    Fry, John
    Agarwal, Kosh
    JOURNAL OF HEPATOLOGY, 2022, 77 : S824 - S824